Timing of Facial Movements for Posed and Spontaneous Facial Expressions
The purpose of this research study is to detect timing differences in movement onset when subjects produce facial expressions either intentionally or spontaneously as a means to determine what brain area is responsible for initiating the facial expression.
For more information about this study, please contact the study coordinator:
Francesca Dino, BA
Email: [email protected]
Phone: (303) 724-6103
Conversational Speech in the Diagnosis of Neurocognitive Disorders
The CSA study is working to develop diagnostic tools using conversational speech, with the hopes of eventually using recorded conversations between primary care doctors and their patients to help detect neurocognitive disease in its early stages. Using elements of conversational speech such as tone of voice and duration of speaking is a cheap, non-invasive way to gather information that can be used to direct medical interventions that will help slow or prevent the progression of neurological disease.
For more information about this study, please contact the study coordinator:
Francesca Dino, BA
Email: [email protected]
Phone: (303) 724-6103
Computational Speech Analysis in Alzheimer's Disease and Related Neurocognitive Disorders
The proposed study is a prospective, longitudinal, observational, cohort investigation of two distinct research groups. The first group is a highly selected and well-characterized research cohort of healthy control, Alzheimer’s disease, and MCI subjects (Group A). Clinical applications of this algorithm will then be assessed in a clinic-based cohort of patients with different NCDs (Group B) in order reduce spectrum bias likely present in prior studies. The overall objective is to develop intuitive, reliable and reproducible CSA-based clinical measures by correlating them with established neuropsychiatric and imaging markers, determining their efficacy in clinical populations, and determining how they change over time. As a result, this research will validate specific speech traits as useful diagnostic markers of neurocognitive disease and explain why those markers differ between patient groups, both of which are major steps towards the design of novel and easily implemented tools in the screening of NCDs such as Alzheimer's disease.
Assessing the knowledge and needs of Colorado healthcare providers regarding dementia and other neurocognitive disorders
With dementia prevalence increasing in an aging population, learning how to meet the needs of patients with dementia is imperative. This study is surveying Colorado primary care physicians to understand how dementia is diagnosed and managed by Colorado’s primary care practices, in order to systematically develop and improve local, regional, and state-wide processes for dementia diagnosis and care.
For more information about this study, please contact Deanna Ragsdale
Email: [email protected]
Phone: (303) 724-2046
Brinker Fund
Currently not enrolling. Please check back later for more information!
Biogen
Phase 3b open-label, multicenter, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205
The primary objective is to evaluate the long-term safety and tolerability of aducanumab after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants). To learn more, visit clinicaltrials.gov
For more information about this study, please contact the study coordinator:
Nelly Solórzano, BS
Email: [email protected]
Phone: (303) 724-3830
Alector
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
Alector, Inc. is studying AL001 as a new experimental drug for frontotemporal dementia (FTD) caused by mutations in the progranulin gene. These mutations reduce progranulin levels in the body and may lead to symptoms of FTD.
The purpose of the phase 3 study is to study if increasing progranulin levels with treatment of AL001 will delay onset of symptoms or slow disease progression, when compared to a placebo (a solution that contains no active AL001 drug).
For more information about this study, please contact the study coordinator:
Natalie Lopez-Esquibel, BS
Email: [email protected]
Phone: (303) 724-7937
Leukine
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (SESAD)
The purpose of this research study is to learn more about the safety and effectiveness of a drug called sargramostim for improving cognitive function and memory in people with Alzheimer’s disease. Sargramostim is an investigational drug, meaning it has not been approved by the FDA to treat Alzheimer’s. This research study hopes to find out more about how sargramostim works within the body over a longer time period than previously studied.
For more information about this study, please contact the study coordinator:
Nelly Solórzano, BS
Email: [email protected]
Phone: (303) 724-3830
